Bacterial induction of proinflammatory cytokines in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 16, Issue 12, 2010, Pages 2173-2179

  Klapproth, Jan Michael A ^a   Sasaki, Maiko ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

bacteria; CBir1; Crohn's disease; cytokine; Escherichia coli; flagellin; inflammatory bowel disease; interleukin; Mycobacterium avium subspecies paratuberculosis; NOD2; Toll like receptors; type I pili; ulcerative colitis

Indexed keywords

BACTERIAL DNA; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CYTOKINE; FLAGELLIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 2;

BACTERIAL FLAGELLUM; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM PILUS; CD4+ T LYMPHOCYTE; CROHN DISEASE; ENTERITIS; ESCHERICHIA COLI; FUSOBACTERIUM VARIUM; HUMAN; INTERFERON PRODUCTION; INTESTINE FLORA; MYCOBACTERIUM PARATUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ULCERATIVE COLITIS; UPREGULATION;

ANIMALS; BACTERIA; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES;

EID: 78649582941     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21332     Document Type: Review

References (71)

1. Baker PI, Love DR, Ferguson LR,. Role of gut microbiota in Crohn's disease. Expert Rev Gastroenterol Hepatol. 2009; 3: 535-546.
2. Rubin DT, Kornblunth A,. Role of antibiotics in the management of inflammatory bowel disease: a review. Rev Gastroenterol Disord. 2005; 5 (suppl 3): S10-15.
3. Harper PH, Lee EC, Kettlewell MG, et al. Role of the faecal stream in the maintenance of Crohn's colitis. Gut. 1985; 26: 279-284.
4. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet. 1991; 338: 771-774.
5. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998; 114: 262-267.
6. Wehkamp J, Schmid M, Fellermann K, et al. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol. 2005; 77: 460-465.
7. Voss E, Wehkamp J, Wehkamp K, et al. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem. 2006; 281: 2005-2011.
8. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut. 2004; 53: 1658-1664.
9. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411: 599-603.
10. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411: 603-606.
11. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007; 39: 596-604.
12. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet. 2007; 39: 830-832.
13. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005; 307: 731-734.
14. Wirtz S, Neurath MF,. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev. 2007; 59: 1073-1083.
15. Mackie RI, Sghir A, Gaskins HR,. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr. 1999; 69: 1035S-1045S.
16. Ley RE, Peterson DA, Gordon JI,. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006; 124: 837-848.
17. Stallmach A, Giese T, Schmidt C, et al. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis. 2004; 19: 308-315.
18. Stucchi A, Reed K, O'Brien M, et al. A new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC. Inflamm Bowel Dis. 2006; 12: 581-587.
19. Holtkamp W, Stollberg T, Reis HE,. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. J Clin Gastroenterol. 1995; 20: 123-126.
20. Bamias G, Martin C 3rd, Marini M, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003; 171: 4868-4874.
21. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004; 113: 1490-1497.
22. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005; 129: 550-564.
23. Nielsen OH, Rudiger N, Gaustadnes M, et al. Intestinal interleukin-8 concentration and gene expression in inflammatory bowel disease. Scand J Gastroenterol. 1997; 32: 1028-1034.
24. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337: 1029-1035.
25. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
26. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
27. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232-1239. (Pubitemid 47300424)
28. Hart AL, Kamm MA, Knight SC, et al. Quantitative and functional characteristics of intestinal-homing memory T cells: analysis of Crohn's disease patients and healthy controls. Clin Exp Immunol. 2004; 135: 137-145.
29. Hvas CL, Kelsen J, Agnholt J, et al. Crohn's disease intestinal CD4+ T cells have impaired interleukin-10 production which is not restored by probiotic bacteria. Scand J Gastroenterol. 2007; 42: 592-601.
30. Llopis M, Antolin M, Carol M, et al. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa. Inflamm Bowel Dis. 2009; 15: 275-283.
31. Keita AV, Salim SY, Jiang T, et al. Increased uptake of non-pathogenic E. coli via the follicle-associated epithelium in longstanding ileal Crohn's disease. J Pathol. 2008; 215: 135-144.
32. Sasaki M, Sitaraman SV, Babbin BA, et al. Invasive Escherichia coli are a feature of Crohn's disease. Lab Invest. 2007; 87: 1042-1054.
33. Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology. 2004; 127: 80-93.
34. Ohkusa T, Yoshida T, Sato N, et al. Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. J Med Microbiol. 2009; 58: 535-545.
35. Andoh A, Sakata S, Koizumi Y, et al. Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. Inflamm Bowel Dis. 2007; 13: 955-962.
36. Subramanian S, Rhodes JM, Hart CA, et al. Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine. Inflamm Bowel Dis. 2008; 14: 162-175.
37. Haraga A, Miller SI,. A Salmonella enterica serovar typhimurium translocated leucine-rich repeat effector protein inhibits NF-kappa B-dependent gene expression. Infect Immun. 2003; 71: 4052-408.
38. Collier-Hyams LS, Zeng H, Sun J, et al. Cutting edge: Salmonella AvrA effector inhibits the key proinflammatory, anti-apoptotic NF-kappa B pathway. J Immunol. 2002; 169: 2846-2850.
39. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004; 127: 412-421.
40. Meconi S, Vercellone A, Levillain F, et al. Adherent-invasive Escherichia coli isolated from Crohn's disease patients induce granulomas in vitro. Cell Microbiol. 2007; 9: 1252-1261.
41. Lapaquette P, Glasser AL, Huett A, et al. Crohn's disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly. Cell Microbiol. 2010; 12: 99-113.
42. Boudeau J, Glasser AL, Masseret E, et al. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect Immun. 1999; 67: 4499-4509.
43. Bringer MA, Glasser AL, Tung CH, et al. The Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 replicates in mature phagolysosomes within J774 macrophages. Cell Microbiol. 2006; 8: 471-484.
44. Glasser AL, Boudeau J, Barnich N, et al. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun. 2001; 69: 5529-5537.
45. La Ferla K, Seegert D, Schreiber S,. Activation of NF-kappaB in intestinal epithelial cells by E. coli strains isolated from the colonic mucosa of IBD patients. Int J Colorectal Dis. 2004; 19: 334-342.
46. Basler T, Geffers R, Weiss S, et al. Mycobacterium avium subspecies induce differential expression of pro-inflammatory mediators in a murine macrophage model: evidence for enhanced pathogenicity of Mycobacterium avium subspecies paratuberculosis. Immunobiology. 2008; 213: 879-888.
47. Clancy R, Ren Z, Turton J, et al. Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-alpha secretion. Dig Liver Dis. 2007; 39: 445-451.
48. Sibartie S, Scully P, Keohane J, et al. Mycobacterium avium subsp. paratuberculosis (MAP) as a modifying factor in Crohn's disease. Inflamm Bowel Dis. 2010; 16: 296-304.
49. Olsen I, Tollefsen S, Aagaard C, et al. Isolation of Mycobacterium avium subspecies paratuberculosis reactive CD4 T cells from intestinal biopsies of Crohn's disease patients. PLoS ONE. 2009; 4: e5641.
50. Barnich N, Boudeau J, Claret L, et al. Regulatory and functional co-operation of flagella and type 1 pili in adhesive and invasive abilities of AIEC strain LF82 isolated from a patient with Crohn's disease. Mol Microbiol. 2003; 48: 781-794.
51. Giron JA, Torres AG, Freer E, et al. The flagella of enteropathogenic Escherichia coli mediate adherence to epithelial cells. Mol Microbiol. 2002; 44: 361-379.
52. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004; 113: 1296-1306.
53. Shen C, Landers CJ, Derkowski C, et al. Enhanced CBir1-specific innate and adaptive immune responses in Crohn's disease. Inflamm Bowel Dis. 2008; 14: 1641-1651.
54. Eaves-Pyles T, Allen CA, Taormina J, et al. Escherichia coli isolated from a Crohn's disease patient adheres, invades, and induces inflammatory responses in polarized intestinal epithelial cells. Int J Med Microbiol. 2008; 298: 397-409.
55. Semiramoth N, Gleizes A, Turbica I, et al. Escherichia coli type 1 pili trigger late IL-8 production by neutrophil-like differentiated PLB-985 cells through a Src family kinase- and MAPK-dependent mechanism. J Leukoc Biol. 2009; 85: 310-321.
56. Baumgart DC, Thomas S, Przesdzing I, et al. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin Exp Immunol. 2009; 157: 423-436.
57. Canto E, Ricart E, Monfort D, et al. TNF alpha production to TLR2 ligands in active IBD patients. Clin Immunol. 2006; 119: 156-165.
58. Noronha AM, Liang Y, Hetzel JT, et al. Hyperactivated B cells in human inflammatory bowel disease. J Leukoc Biol. 2009; 86: 1007-1016.
59. Pastor Rojo O, Lopez San Roman A, Albeniz Arbizu E, et al. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 269-277.
60. Gutierrez A, Frances R, Amoros A, et al. Cytokine association with bacterial DNA in serum of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 508-514.
61. van Heel DA, Ghosh S, Hunt KA, et al. Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut. 2005; 54: 1553-1557.
62. Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet. 2006; 367: 668-678.
63. Rennick D, Davidson N, Berg D,. Interleukin-10 gene knock-out mice: a model of chronic inflammation. Clin Immunol Immunopathol. 1995; 76: S174-178.
64. Wohlgemuth S, Haller D, Blaut M, et al. Reduced microbial diversity and high numbers of one single Escherichia coli strain in the intestine of colitic mice. Environ Microbiol. 2009; 11: 1562-1571.
65. Barnich N, Carvalho FA, Glasser AL, et al. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest. 2007; 117: 1566-1574.
66. Carvalho FA, Barnich N, Sivignon A, et al. Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med. 2009; 206: 2179-2189.
67. Carvalho FA, Barnich N, Sauvanet P, et al. Crohn's disease-associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin. Inflamm Bowel Dis. 2008; 14: 1051-1060.
68. Cong Y, Weaver CT, Lazenby A, et al. Colitis induced by enteric bacterial antigen-specific CD4+ T cells requires CD40-CD40 ligand interactions for a sustained increase in mucosal IL-12. J Immunol. 2000; 165: 2173-2182.
69. Elson CO, Cong Y, Weaver CT, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007; 132: 2359-2370.
70. Siegmund B,. Targeted therapies in inflammatory bowel disease. Dig Dis. 2009; 27: 465-469.
71. Singh UP, Singh S, Singh R, et al. Influence of Mycobacterium avium subsp. paratuberculosis on colitis development and specific immune responses during disease. Infect Immun. 2007; 75: 3722-3728.